|
Total MIPS Economic Impact (not including job creation)
Sales and revenue for the top-five MIPS-related
project companies (partial listing) |
$9.8 billion |
| R&D spending on MIPS projects |
$135.6 million |
| Start-up company impact |
$170.9 million |
| Direct economic benefit |
$10 billion |
Company |
MIPS-Related Product |
Revenue/Sales |
| MedImmune |
Synagis |
$4.4 billion * |
| Martek Biosciences |
Infant formula additive oils |
$566.7 million ** |
| Navmar Applied Sciences |
MAKO UAV |
$10.1 million *** |
| Hughes Network Systems |
DIRECWAY |
$4.8 billion **** |
| Black & Decker |
Bullet Speed Tip Masonry Drill Bit |
***** |
| Total: |
|
$9.8 billion |
* Total reported sales of Synagis since 1998
** Total revenue for Martek from 1993-2005, dominated by infant formula additive sales
*** Includes Navy contract and 30 units shipped
**** Total available reported Network Systems revenue of the DirecTV Group since 2001, dominated by DIRECWAY sales
***** Total Power Tools and Accessories Sales was $16.4 billion from 2001-2004. The company does not provide sales figures for individual products.
 More MIPS impact
MTES impacts Maryland’s economy by $ 97.2 million
Based on NIST MEP surveys from January 2000 through December 2005, MTES has assisted Maryland manufacturers in:
• Increasing sales by- $18.3 M
• Retaining sales by - $54.5 M
• Saving on costs by - $5.8 M
• Saving on investments made by - $1.2 M
• Avoiding unnecessary investments of - $8.8 M
• Increasing investment in plants or equipment by - $8.6 M
• Creating or retaining jobs by – 806 employees
More MTES impact
Over 800 fermentations conducted since 1998.
Large Biotechnology Companies Utilizing the Program Extensively
• Martek Biosciences, Inc.
• MedImmune, Inc.
• Digene Corporation
• More…
Government Facilities Utilizing the Program Extensively
• National Institutes of Health
• National Institute of Standards and Technology
• U.S. Army.
• More…
"When I came to Ed Sybert [industry director of the BSF] 10 or 12 years ago, Martek had developed this fermentable algae. We were getting into the next stage where we said 'will this stuff actually scale-up?' If it doesn’t scale up, we thought, if the economics aren't good, if it doesn't make pure products, if the organism doesn't grow well—we’re sunk. We didn't have the equipment; we didn't have the people. Ed said let's see if we can make this work. And it did! Over 6 million babies have now had this material. Over 70 percent of the infant formula in the United States has it. It all started here. It all came from this facility."
o Henry "Pete" Linsert, Chairman and CEO of Martek Biosciences, Inc. NASDAQ (MATK)
More BREP impact
- 407 award winners, examiners since 1983
MPEA program past examiners
MPEA program past award winners |
